P/E ratio for Anika Therapeutics (ANIK)
P/E ratio as of April 2024 (TTM): -16.7
According to Anika Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.6993. At the end of 2022 the company had a P/E ratio of -28.7.
P/E ratio history for Anika Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -28.7 | -123.26% |
| 2021 | 124 | -558.61% |
| 2020 | -26.9 | -200.28% |
| 2019 | 26.9 | 3.91% |
| 2018 | 25.9 | 4.55% |
| 2017 | 24.7 | 12.13% |
| 2016 | 22.1 | 19.05% |
| 2015 | 18.5 | 19.13% |
| 2014 | 15.5 | -38.88% |
| 2013 | 25.4 | 125.22% |
| 2012 | 11.3 | -25.08% |
| 2011 | 15.1 | -23.15% |
| 2010 | 19.6 | -17.72% |
| 2009 | 23.8 | 158.83% |
| 2008 | 9.21 | -65.81% |
| 2007 | 26.9 | -14.72% |
| 2006 | 31.6 | 54.06% |
| 2005 | 20.5 | 121.9% |
| 2004 | 9.24 | -92.41% |
| 2003 | 122 | -3912.37% |
| 2002 | -3.19 | 117.16% |
| 2001 | -1.47 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -162.13% | 🇺🇸 USA |
 Medtronic MDT | 29.3 | -275.55% | 🇮🇪 Ireland |
 Stryker Corporation SYK | 49.3 | -395.00% | 🇺🇸 USA |
 STAAR Surgical STAA | 112 | -769.26% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | 22.2 | -232.91% | 🇺🇸 USA |
 Hill-Rom HRC | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.